Topic:

R&D

Latest Headlines

Latest Headlines

UPDATED: Prosensa harvests $78M as biotech IPOs continue to sizzle

Prosensa picked the right day to price its IPO. The Dutch biotech rang up the offering at $13 a share, at the top of the range, raising $78 million after bumping the number of shares on offer to 6 million. The stock will trade on Nasdaq as "RNA."

Resverlogix stock craters on failure of cardio drug trial

Resverlogix fell hard this afternoon on news that the company fell short in a midstage study of its lead HDL cholesterol-boosting drug. The Calgary-based biotech company said the Phase IIb study of RVX-208 failed to meet the goal of change in percent of atheroma volume in patients with a high risk of developing cardiovascular disease.

J&J backs two biotech startups, inaugurates innovation center

The Cambridge, MA, center is one of four planned by J&J.

Lilly pours another $10M into public-private Indiana research institute

Eli Lilly is pitching in $10 million to fund the Indiana Biosciences Research Institute, a public-private life sciences organization launched by local luminaries Cook Medical, Biomet and Roche Diagnostics.

'Reverse' DNA vaccine bursts into the spotlight with promising Type 1 diabetes data

A stealth biotech spun out of Stanford University burst into public view today, drawing headlines around the world for its new therapeutic approach to Type 1 diabetes that aims to completely change the standard of care in the field.

Type 1 diabetes vaccine impresses in early study

Diabetes treatments either fail to stop the decline of insulin-releasing cells, or put patients at risk by shutting off other bits of the immune system too. New data suggest that DNA vaccines could help preserve the remaining pancreatic insulin-producing beta cells without causing serious side effects.

Middle Peak hauls in $8.5M for mitral device

California startup Middle Peak Medical locked down an $8.5 million Series A to support the development of its device to treat mitral regurgitation, targeting a market haunted by Abbott Laboratories.

With lead drug from Pfizer, Esperion shares jump in expanded $70M biotech IPO

Esperion Therapeutics got a warm reception after an upsized IPO that hauled in $70 million. The Plymouth, MI-based biotech company increased the offering size from 4.5 million to 5 million shares at $14 per share, hitting the midpoint of its proposed range of $13 to $15 per share.

Takeda takes pole position in norovirus vaccine development

Cruise ships, take heart. Takeda Pharmaceuticals is leading the efforts to develop a vaccine against norovirus, the vomiting bug that has crippled pleasure ships and afflicted schools.

Takeda takes aim at new vomiting-bug vaccine

his experimental vaccine combines components of two types of norovirus, which Takeda believes should provide an effective guard against all the viral strains in circulation.